Medigene AG (MDG1.DE) XETRA
0.13
-0.051(-27.64%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Medigene AG
Sector
Healthcare
Industry
Biotechnology
Employees
87
First IPO Date
June 30, 2000
Key Executives
| Name | Title | Pay | Year Born |
| Selwyn | Chief Executive Officer & Chairman of Executive Management Board | 429,000 | 1971 |
| Ernst-Ludwig Winnacker | Co-Founder & Chairman Scientific Advisory Board | 20,000 | 1941 |
| Dolores J. Schendel | Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development | 470,000 | N/A |
| Pamela Keck | Vice President of Investor Relations & Corporation Communications | 0 | N/A |
| Birger Kohlert | Chief Financial Officer | 0 | N/A |
| Kirsty Crame | Vice President and Head of Clinical Research & Development | 0 | N/A |
Description
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
